Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[ 18 F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide ( 18 F-VUIIS1018A) to Image Glioma

Abstract

Purpose: There is an urgent need for the development of novel positron emission tomography (PET) tracers for glioma imaging. In this study, we developed a novel PET probe ([ 18 F]VUIIS1018A) by targeting translocator protein (TSPO), an imaging biomarker for glioma. The purpose of this preclinical study was to evaluate this novel TSPO probe for glioma imaging. Procedures: In this study, we synthesized [ 19 F]VUIIS1018A and the precursor for radiosynthesis of [ 18 F]VUIIS1018A. TSPO binding affinity was confirmed using a radioligand competitive binding assay in C6 glioma cell lysate. Further, dynamic imaging studies were performed in rats using a microPET system. These studies include displacement and blocking studies for ligand reversibility and specificity evaluation, and compartment modeling of PET data for pharmacokinetic parameter measurement using metabolite-corrected arterial input functions and PMOD. Results: Compared to previously reported TSPO tracers including [ 18 F]VUIIS1008 and [ 18 F]DPA-714, the novel tracer [ 18 F]VUIIS1018A demonstrated higher binding affinity and BP ND . Pretreatment with the cold analog [ 19 F]VUIIS1018A could partially block tumor accumulation of this novel tracer. Further, compartment modeling of this novel tracer also exhibited a greater tumor-to-background ratio, a higher tumor binding potential and a lower brain binding potential when compared with other TSPO probes, such as [ 18 F]DPA-714 and [ 18 F]VUIIS1008. Conclusions: These studies illustrate that [ 18 F]VUIIS1018A can serve as a promising TSPO PET tracer for glioma imaging and potentially imaging of other solid tumors.